ADA: GLP-1 Receptor Agonist Use Beneficial in Adults With Obesity, Autoimmune Disease

MONDAY, June 8, 2026-- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according...